Interestingly, expression of several clock genes is dysregulated in human PDA patient tumors and decreased expression of circadian transcription factor BMAL1 is a predictor of tumor progression, suggesting that metabolic reprogramming in PDA might drive cancer progression in part through dysregulation of the circadian clock (12, 28). This evidence concerns the gene CLOCK and Patent ductus arteriosus.